On Jul. 23, 1993, Chiron and Berlex Laboratories announced that the U.S. Food and Drug Administration (FDA) had approved Chiron’s Betaseron as the first treatment for multiple sclerosis in 20 years.

That approval was later expanded in 2006 to include clinically isolated syndrome (CIS), and in 2019 to cover active secondary progressive MS (SPMS).